Regulation of Stroke Volume (Preload, Contractility & Afterload) & Heart Failure
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CH
Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CHIBA, M.D., Miyoharu KOBAYASHI, M.D., Masahiro SHIMOTORI,M.D., Yasuyuki FURUKAWA, M.D., and Kimiaki SAEGUSA, M.D. SUMMARY When dilazep was administered intravenously to the anesthe- tized donor dog, mean systemic blood pressure was dose depend- ently decreased. At a dose of 0.1mg/Kg i.v., the mean blood pressure was not changed but a slight decrease in heart rate was usually observed in the donor dog. At the same time, a slight but significant decrease in atrial rate and developed tension of the iso- lated atrium was induced. Within a dose range of 0.3 to 1mg/Kg i.v., dilazep caused a dose related decrease in mean blood pressure, bradycardia in the donor dog, and negative chronotropic, dromo- tropic and inotropic effects in the isolated atrium. At larger doses of 3 and 10mg/Kg i.v., dilazep caused marked hypotension, fre- quently with severe sinus bradycardia or sinus arrest, especially in isolated atria. When dilazep was infused intraarterially at a rate of 0.2-1 ƒÊ g/min into the cannulated sinus node artery of the isolated atrium, negative chrono- and inotropic effects were dose dependently in- duced. With respect to dromotropism, SA conduction time (SACT) was prolonged at infusion rates of 0.2 and 0.4ƒÊg/min. But at 1ƒÊg, dilazep caused an increase or decrease of SACT, indicating a shift of the SA nodal pacemaker. It is concluded that dilazep has direct negative chrono-, dromo- and inotropic properties on the heart at doses which produced no significant hypotension. -
Hemodynamic Monitoring and Circulatory Assist Devices
Hemodynamic Monitoring Hemodynamic Monitoring and Circulatory Assist Devices • Measurement of pressure, flow, and oxygenation within the cardiovascular system • Includes invasive and noninvasive measurements (Relates to Chapter 66, – Systemic and pulmonary arterial pressures “Nursing Management: Critical Care,” in the textbook) Hemodynamic Monitoring Hemodynamic Monitoring • Invasive and noninvasive measurements • Invasive and noninvasive measurements (cont’d) (cont’d) – Central venous pressure (CVP) – Stroke volume (SV)/stroke volume index (SVI) – Pulmonary artery wedge pressure (PAWP) – O2 saturation of arterial blood (SaO2) – Cardiac output (CO)/cardiac index (CI) – O2 saturation of mixed venous blood (SvO2) Hemodynamic Monitoring Hemodynamic Monitoring General Principles General Principles • Preload: Volume of blood within ventricle at • Contractility: Strength of ventricular end of diastole contraction • Afterload: Forces opposing ventricular • PAWP: Measurement of pulmonary capillary ejection pressure; reflects left ventricular end‐diastolic – Systemic arterial pressure pressure under normal conditions – Resistance offered by aortic valve – Mass and density of blood to be moved 1 Hemodynamic Monitoring Principles of Invasive Pressure General Principles Monitoring • CVP: Right ventricular preload or right • Equipment must be referenced and zero ventricular end‐diastolic pressure under balance to environment and dynamic normal conditions, measured in right atrium response characteristics optimized or in vena cava close to heart • -
Cardiovascular System: Heart
Cardiovascular System: Heart Cardiovascular System – Heart Conducting cells: Cardiac Electrophysiology Cardiac cells specialized to quickly spread action potentials across myocardium • Weak force generators System allows for orderly, sequential depolarization and Intrinsic Conduction System: contraction of heart Normal sinus rhythm: 1) AP originates at SA node 2) SA node fires at 60 – 100 beats / min Atrial internodal tracts Sinoatrial node: (SA node) 3) Correct myocardial activation sequence • Located in right atrial wall • Initiates action potentials (APs) • Pacemaker (~ 80 beats / min) Bundle branches Atrioventricular node: (AV Node) • Connects atria to ventricles • Slowed conduction velocity • Ventricular filling Purkinje Bundle of His fibers Marieb & Hoehn (Human Anatomy and Physiology, 8th ed.) – Figure 18.14 1 Cardiovascular System – Heart Cardiac Electrophysiology The autonomic nervous system can directly affect the heart rate; these effects are called chronotropic effects Recall: spontaneous depolarization = VG Na+ channels Positive chronotrophic effects: (increase heart rate) • Under sympathetic control Leads to g ; cells SA Na NE node reach threshold more rapidly Sinoatrial node Pharmacology: β1 receptors β-blockers (e.g., propanolol) Negative chronotrophic effects: (decrease heart rate) • Under parasympathetic control Leads to gNa; cells reach threshold SA less rapidly ACh node Leads to gK; cells hyperpolarized during Muscarinic receptors repolarization stage (further from threshold) Costanzo (Physiology, 4th ed.) – Figure -
Time-Varying Elastance and Left Ventricular Aortic Coupling Keith R
Walley Critical Care (2016) 20:270 DOI 10.1186/s13054-016-1439-6 REVIEW Open Access Left ventricular function: time-varying elastance and left ventricular aortic coupling Keith R. Walley Abstract heart must have special characteristics that allow it to respond appropriately and deliver necessary blood flow Many aspects of left ventricular function are explained and oxygen, even though flow is regulated from outside by considering ventricular pressure–volume characteristics. the heart. Contractility is best measured by the slope, Emax, of the To understand these special cardiac characteristics we end-systolic pressure–volume relationship. Ventricular start with ventricular function curves and show how systole is usefully characterized by a time-varying these curves are generated by underlying ventricular elastance (ΔP/ΔV). An extended area, the pressure– pressure–volume characteristics. Understanding ventricu- volume area, subtended by the ventricular pressure– lar function from a pressure–volume perspective leads to volume loop (useful mechanical work) and the ESPVR consideration of concepts such as time-varying ventricular (energy expended without mechanical work), is linearly elastance and the connection between the work of the related to myocardial oxygen consumption per beat. heart during a cardiac cycle and myocardial oxygen con- For energetically efficient systolic ejection ventricular sumption. Connection of the heart to the arterial circula- elastance should be, and is, matched to aortic elastance. tion is then considered. Diastole and the connection of Without matching, the fraction of energy expended the heart to the venous circulation is considered in an ab- without mechanical work increases and energy is lost breviated form as these relationships, which define how during ejection across the aortic valve. -
Left Ventricular Assist Device
Left Ventricular Assist Device PHI 2016 Objectives • Discuss conditions to qualify for LVAD Therapy • Discuss LVAD placement and other treatment modalities • Describe the Thoratec Heartmate 2 and Heartmate 3 systems • Discuss assessment changes of the LVAD patient • Review emergency care of the LVAD patient Stage C or D Heart Failure slide 3 LVAD Exclusion Criteria • Aortic Valve Competency – Sometimes valve is oversewn to allow adequate device function • RV Function- if RV dysfunction is present must be transplant candidate – No PPHTN unless candidate for heart-lung transplant • Hepatic Dysfunction- cirrhosis and portal HTN • Renal Dysfunction- Irreversible disease vs. disease due to poor perfusion – Long term dialysis and creatinine > 3.0 mg/dl • Cancer • Psych/Social Concerns slide 4 LVAD Referral • Symptoms • Hypotension – Recurrent admissions • Laboratory – Refractory • Renal insufficiency – At rest • Hepatic dysfunction • Medications • Hyponatremia – Intolerance or lower doses • Pulmonary Hypertension • ACE-I/ARBs • RV Dysfunction • Beta blockers • Unresponsiveness to CRT – Increasing diuretic doses (Cardiac Resynchronization Therapy) • Unable to carry out ADLs – Poor nutritional status • Inotropes slide 5 INTERMACS Classification slide 9 LVAD Implantation Process • Referral Phase – Referred to AHFC by primary cardiologist • Evaluation Phase (2-4 weeks) – Testing – Consults with each team member – Selection Committee meets weekly • Surgery Phase (~4-6 weeks) – Admit to CCU the day before surgery • Outpatient Phase – Weekly clinic -
Static and Dynamic Components of Right Ventricular Afterload Are Negatively Associated with Calf Survival at High Altitude1
Published September 29, 2016 Static and dynamic components of right ventricular afterload are negatively associated with calf survival at high altitude1 J. M. Neary,*2 R. D. Brown,† T. N. Holt,‡ K. R. Stenmark,† R. M. Enns,§ M. G. Thomas,§ and F. B. Garry‡ *Department of Animal and Food Sciences, College of Agricultural Sciences and Natural Resources, Texas Tech University, Lubbock 79409-2141; †Division of Pediatric Critical Care, School of Medicine, University of Colorado Denver, Aurora 80045; ‡Integrated Livestock Management, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1678 Campus Delivery, Fort Collins 80523-1678; and, §Department of Animal Sciences, The College of Agricultural Sciences, Colorado State University, Fort Collins 80523-1171. ABSTRACT: The purposes of this study were to pulse pressures (P = 0.03) at 3 mo of age than calves evaluate mean, systolic, and diastolic pulmonary that survived to 7 mo. Calves presumed to have died arterial pressures; pulmonary arterial pulse pres- tended to have greater systemic oxygen extraction sures; and systemic oxygen extraction fraction as fractions at 3 mo of age than calves that survived (P risk factors for the survival of suckling calves on one = 0.13). Diastolic pressure was not associated with ranch located at an altitude of 2,730 m in Colorado, survival (P = 0.27). Mean pulmonary arterial pres- USA. A prospective cohort study of 58 calves was sure is predominantly determined by static resistance performed. Pulmonary arterial pressures and sys- attributable to distal pulmonary arterial remodeling. temic oxygen extraction were measured when calves Pulse pressure and systolic pulmonary arterial pres- were approximately 3 mo (86 ± 7 d) and 7 mo (197 sure represents the dynamic or oscillatory resistance ± 6 d) of age. -
Quantitative Electrocardiography for Prediction Of
QUANTITATIVE ELECTROCARDIOGRAPHY FOR PREDICTION OF POSTOPERATIVE ATRIAL FIBRILLATION AFTER CARDIAC SURGERY by FLORIAN RADER, M.D. Submitted in partial fulfillment of the requirements For the degree of Master of Science Clinical Research Scholars Program CASE WESTERN RESERVE UNIVERSITY January 2010 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Florian Rader, M.D. candidate for the Master of Science degree*. (signed) Regis E. McFadden (chair of the committee) Eugene H. Blackstone, M.D. Ottorino Costantini, M.D. Neal Dawson, M.D. (date) 10-28-2009 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 Table of Contents List of Tables 4 List of Figures 5 Acknowledgments 6 List of Abbreviations 7 Abstract 9 Text Background and Significance 10 Specific aims 12 Methods 13 Results 21 Discussion 46 Limitations 54 Conclusions 54 References 55 3 List of Tables: Table 1: Patient characteristics 24 Table 2: Clinical predictors of postoperative atrial fibrillation 37 Table 3: ECG predictors of postoperative atrial fibrillation 38 4 List of Figures: Figure 1: Relationship of anatomic and ECG changes with POAF 11 Figure 2: Patient flow chart 22 Figure 3: Occurrence of POAF by days after surgery 33 Figure 4: Occurrence of POAF by surgery type 34 Figure 5: ROC curve of final prediction model 35 Figure 6: Calibration curve of final prediction model 36 Figure 7: Adjusted Co-plots of ECG predictors 39 Figure 8: Unadjusted and adjusted co-plot of P wave amplitude 41 Figure 9: Nomogram of final prediction model 42 Figure 10: Nomogram of prediction model with pre-op variables 43 Figure 11: Calibration curve of model without ECG predictors 45 Figure 12: Left atrial sizes by P wave amplitude in aVR 48 Figure 13: Correlation matrix (P wave amplitude, aVR, and left atrial volume) 49 5 Acknowledgments: I thank Dr. -
Effects of Neuronal Nitric Oxide Synthase Signaling on Myocyte
Effects of Neuronal Nitric Oxide Synthase Signaling on Myocyte Contraction during β- Adrenergic Stimulation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Lifei Tang Biophysics Graduate Program The Ohio State University 2013 Dissertation Committee: Dr. Mark T. Ziolo, PhD Advisor Dr. Brandon Biesiedecki, PhD Dr. Jonathan Davis, PhD Dr. Sandor Gyorke, PhD a Copyright by Lifei Tang 2013 i ABSTRACT Nitric oxide (NO) is known to be a key regulator of cardiac contraction. Within ventricular myocytes, NO is produced by two constitutively expressed NO synthase (NOS) isozymes, NOS1 and NOS3. It is well defined that NOS1 signaling results in positive inotropic and lusitropic effects under baseline conditions. This effect is largely due to the phosphorylation of phospholamban (PLB) at Ser16 by the cAMP-dependent protein kinase (PKA) up-regulating sarcoplasmic reticulum (SR) Ca2+ uptake. In addition, our lab also demonstrated that NOS1 increases ryanodine receptor (RyR) activity via S-nitrosylation up- regulating SR Ca2+ release. Physiologically, heart function is largely regulated by the β-adrenergic (β-AR) pathway leading to positive inotropy and lusitropy. Alterations in the β-AR pathway contribute to the contractile dysfunction, adverse remodeling, and arrhythmias in many cardiac diseases (i.e. heart failure (HF)). The purpose of this dissertation is to investigate the role of NOS1 signaling during β-AR stimulation. Previous studies have shown that NOS1 signaling contributes to the positive inotropy, but not lusitropy, during β-AR stimulation. Interestingly, unlike under baseline conditions, PLB phosphorylation is not altered in the condition of NOS1 deficiency (acute NOS1 inhibition or NOS1 knockout) during β-AR stimulation. -
Chapter 9 Monitoring of the Heart and Vascular System
Chapter 9 Monitoring of the Heart and Vascular System David L. Reich, MD • Alexander J. Mittnacht, MD • Martin J. London, MD • Joel A. Kaplan, MD Hemodynamic Monitoring Cardiac Output Monitoring Arterial Pressure Monitoring Indicator Dilution Arterial Cannulation Sites Analysis and Interpretation Indications of Hemodynamic Data Insertion Techniques Systemic and Pulmonary Vascular Resistances Central Venous Pressure Monitoring Frank-Starling Relationships Indications Monitoring Coronary Perfusion Complications Electrocardiography Pulmonary Arterial Pressure Monitoring Lead Systems Placement of the Pulmonary Artery Catheter Detection of Myocardial Ischemia Indications Intraoperative Lead Systems Complications Arrhythmia and Pacemaker Detection Pacing Catheters Mixed Venous Oxygen Saturation Catheters Summary References HEMODYNAMIC MONITORING For patients with severe cardiovascular disease and those undergoing surgery associ- ated with rapid hemodynamic changes, adequate hemodynamic monitoring should be available at all times. With the ability to measure and record almost all vital physi- ologic parameters, the development of acute hemodynamic changes may be observed and corrective action may be taken in an attempt to correct adverse hemodynamics and improve outcome. Although outcome changes are difficult to prove, it is a rea- sonable assumption that appropriate hemodynamic monitoring should reduce the incidence of major cardiovascular complications. This is based on the presumption that the data obtained from these monitors are interpreted correctly and that thera- peutic decisions are implemented in a timely fashion. Many devices are available to monitor the cardiovascular system. These devices range from those that are completely noninvasive, such as the blood pressure (BP) cuff and ECG, to those that are extremely invasive, such as the pulmonary artery (PA) catheter. To make the best use of invasive monitors, the potential benefits to be gained from the information must outweigh the potential complications. -
Chronic Chagasic Cardiomyopathy (CCC) with Severe Biventricular Involvement and Intraventricular Dromotropic Disturbances
Chronic Chagasic Cardiomyopathy (CCC) with severe biventricular involvement and intraventricular dromotropic disturbances Andrés Ricardo Pérez-Riera, M.D. Ph.D. Raimundo Barbosa-Barros, MD Design of Studies and Scientific Writing Chief of the Coronary Center of the Hospital de Messejana Dr. Carlos Laboratory in the ABC School of Medicine, Alberto Studart Gomes. Fortaleza – CE- Brazil Santo André, São Paulo, Brazil https://ekgvcg.wordpress.com Portuguese Relato de caso Paciente de 29 anos, branca, procedente de área rural endêmica, casa de pau a pique, vários membros da família infectados, portadora de miocardiopatia chagásica crônica com quadro clínico de severa cardiopatia dilatada em classe funcional IV, mesmo com medicação plena. ECO: severo comprometimento da função sistólica biventricular por hipocinesia difusa e fração de ejeção do VE = 22%. Insuficiência mitral e tricúspide ostial severas; diâmetro diastólico do VE = 4.7 Altura / cm / m, pressão sistólica da artéria pulmonar = 44 mmHg. Em uso regular de carvedilol 25 mg 2xdia, furosemida 40 mg 2xdia, espironolactona 25 mgxdia, maleato de enalapril 20 mg 2xdia, amiodarona 100 mg x dia, ácido acetilsalicílico 100 mg x dia. Perguntas: 1. Qual o diagnóstico ECG/VCG? 2. Qual a conduta adequada? English Case report 29-year-old, female, Caucasian, from an endemic rural área for Chagas disease, a stick-up house, several family members infected, carrier of chronic chagasic cardiomyopathy with clinical signs of severe dilated cardiomyopathy functional class IV, even with full medication. ECO: severe impairment of biventricular systolic function due to diffuse hypokinesia and LV ejection fraction = 22%. Severe ostial mitral regurgitation and tricuspid insufficiency; LV diastolic diameter = 4.7 LV/ height/cm/m, pulmonary artery systolic pressure = 44 mmHg. -
Calcium Channel Blockers (Ccbs)
DRUG CLASSES CALCIUM CHANNEL BLOCKERS Calcium channel blockers (CCBs) or calcium antagonists, are among the most widely used drugs in cardiovascular medicine with roles not only in hypertension but also in angina and (for some CCBs) tachyarrhythmias. Examples Amlodipine Diltiazem Felodipine Isradipine Lacidipine Lercanidipine Nicardipine Nifedipine Nisoldipine Verapamil Mechanism of action CCBs promote vasodilator activity (and reduce blood pressure) by reducing calcium influx into vascular smooth muscle cells by interfering with voltage-operated calcium channels (and to a lesser extent receptor-operated channels) in the cell membrane. Interference with intracellular calcium influx is also important in cardiac muscle, cardiac conduction tissue and gastrointestinal smooth muscle. In cardiac tissues, CCBs have potential for negative inotropic, chronotropic and dromotropic activity while the gastrointestinal effects predispose to constipation. These effects vary with different agents according to ability to penetrate cardiac and other tissues, relative affinity for calcium channels in different tissues and the influence of reflux cardiac stimulation secondary to peripheral vasodilation. 1 Although often considered as a single class, CCBs can be subdivided according to structural and functional distinctions. Dihydropyridine derivates : amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nisoldipine Phenylalkylamine : verapamil Benzothiazepine derivative : diltiazem Dihydropyridine derivatives have pronounced -
Dynamic Auscultation
TOP 10 TAKEAWAYS… Jane A. Linderbaum MS, APRN, CNP, AACC Assistant Professor of Medicine Department of cardiovascular disease No Disclosures No off-label discussions 73% of survey respondents identified a need for improved knowledge of CV pathophysiology #10 CARDIAC CIRCULATION, KNOW IT AND LOVE IT The Cardiac Cycle The heart sounds • S1 Mitral (and tricuspid) valve closure Soft if poor EF, loud if good EF • S2 Aortic and pulmonary valve closure Loud if aortic (pulm) pressure • S3 – means “restrictive” filling • S4 – means “abnormal” filling Listening Posts for Auscultation AV – 2nd RICS PV – 2nd LICS MV – 5-6th LICS @ the apex TV – 5-6th LICS parasternal 83% of survey respondents identified themselves as early career in clinic/hospital consult practices # 9 COMMON SYSTOLIC MURMURS YOU WILL DIAGNOSE AND MANAGE MITRAL REGURGITATION MR Treatment • Treat underlying conditions • Consider MV repair when possible at experienced center • Consider MV replacement before ventricle dilates and/or function decreases MITRAL VALVE PROLAPSE Mitral Valve Prolapse Pearls • CHANGE in Murmur (from click-murmur or isolated late sys murmur to holosystolic without audible click) • Skeletal deformities in up to 50% • Upright posture enhances auscultation of the mid-late systolic murmur • May develop severe MR, refer for additional testing as patient may be candidate for mitral valve repair • Murmur may INCREASE with Valsalva • Typically do not require SBE prophylaxis Hypertrophic Cardiomyopathy Hypertrophic Cardiomyopathy • Vigorous LV apical impulse – sustained